ECLIPSENCT06354868
A Study to Assess utiLity of BIoEP as an Early Prognostic Indicator for Predicting Anti-Seizure Medication (ASM) Efficacy
At risk: Primary completion moved at least 9 months later, primary endpoint(s) modified.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion dates pushed to Sep 30, 2027 Show 8 more changesShow less
- Primary endpoint(s) modified
- Recruitment opened
- Start date changed from estimate of Sep 2024 to Mar 24, 2025
- Eligibility criteria expanded, about 79 words
- Enrollment increased: 158 → 198 participants
- Trial sites expanded: 0 → 9 locations
- Secondary endpoint revised
- Study description revised
- Notable Start date: Jun 2024 to Sep 2024v3
- Notable Primary endpoint revised
- Secondary endpoint revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
The association between BioEP and self-reported seizure control
Timeframe: 6 months
Secondary (1)
Association between the 6-month change from baseline in BioEP result and the patients reported global impression of change
Sites
9 sites in 1 country